September 23, 2024 10:48 AM EDT
News Briefing

Con­text makes a T cell en­gager deal; Gink­go Bioworks back­ers have a new SPAC

ENDPOINTS

Plus, news about Longevi­ty Bio­med­ical, Sen­so­ri­on, Te­va and Bris­tol My­ers Squibb:

Con­text Ther­a­peu­tics buys a T cell en­gager: The biotech will

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Q&A: Bris­tol My­ers’ tech chief on the promis­es and per­ils of AI bio

As­traZeneca, Dai­ichi’s TROP2 drug miss­es over­all sur­vival goal in Phase 3 breast can­cer tri­al

Is Sanofi mak­ing a move in­to obe­si­ty? French phar­ma in­vests $27M in­to Ven­tyx

Reg­u­la­to­ry RNA start­up CAMP4 files for IPO as more biotechs line up list­ings

Black Di­a­mond treads wa­ter on small snap­shot of Phase 2 lung can­cer da­ta

sponsored

PD­Cs vs. AD­Cs: A New Fron­tier in Tar­get­ed Can­cer Ther­a­pies and the Po­ten­tial for De­vel­op­ment Part­ner­ships

A service from the Financial Times